NVAX
Price
$4.28
Change
-$0.02 (-0.47%)
Updated
Apr 12, 6:59 PM EST
22 days until earnings call
SYRE
Price
$37.49
Change
-$1.10 (-2.85%)
Updated
Apr 12, 6:59 PM EST
Ad is loading...

Compare trend and price NVAX vs SYRE

Header iconNVAX vs SYRE Comparison
Open Charts NVAX vs SYREBanner chart's image
Novavax
Price$4.28
Change-$0.02 (-0.47%)
Volume$2.43M
CapitalizationN/A
Spyre Therapeutics
Price$37.49
Change-$1.10 (-2.85%)
Volume$196.68K
CapitalizationN/A
View a ticker or compare two or three
NVAX vs SYRE Comparison Chart

Loading...

NVAXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
SYREDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
NVAX vs. SYRE commentary
Apr 15, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVAX is a Hold and SYRE is a Hold.

COMPARISON
Comparison
Apr 15, 2024
Stock price -- (NVAX: $4.65 vs. SYRE: $37.06)
Brand notoriety: NVAX: Notable vs. SYRE: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NVAX: 52% vs. SYRE: 30%
Market capitalization -- NVAX: $650.78M vs. SYRE: $1.37B
NVAX [@Biotechnology] is valued at $650.78M. SYRE’s [@Biotechnology] market capitalization is $1.37B. The market cap for tickers in the [@Biotechnology] industry ranges from $568.84B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVAX’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 1 green FA rating(s).

  • NVAX’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 1 green, 4 red.
According to our system of comparison, SYRE is a better buy in the long-term than NVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVAX’s TA Score shows that 5 TA indicator(s) are bullish while SYRE’s TA Score has 3 bullish TA indicator(s).

  • NVAX’s TA Score: 5 bullish, 4 bearish.
  • SYRE’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, NVAX is a better buy in the short-term than SYRE.

Price Growth

NVAX (@Biotechnology) experienced а -3.33% price change this week, while SYRE (@Biotechnology) price change was -3.69% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.71%. For the same industry, the average monthly price growth was +6.49%, and the average quarterly price growth was +103.81%.

Reported Earning Dates

NVAX is expected to report earnings on May 07, 2024.

SYRE is expected to report earnings on Nov 09, 2023.

Industries' Descriptions

@Biotechnology (+4.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for NVAX with price predictions.
OPEN
A.I.dvisor published
a Summary for SYRE with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
SYRE($1.37B) has a higher market cap than NVAX($651M). SYRE YTD gains are higher at: 72.212 vs. NVAX (-3.125). SYRE has higher annual earnings (EBITDA): -127.82M vs. NVAX (-487.39M). NVAX has more cash in the bank: 569M vs. SYRE (339M). SYRE has less debt than NVAX: SYRE (0) vs NVAX (229M). NVAX has higher revenues than SYRE: NVAX (556M) vs SYRE (886K).
NVAXSYRENVAX / SYRE
Capitalization651M1.37B47%
EBITDA-487.39M-127.82M381%
Gain YTD-3.12572.212-4%
P/E RatioN/AN/A-
Revenue556M886K62,754%
Total Cash569M339M168%
Total Debt229M0-
FUNDAMENTALS RATINGS
NVAX vs SYRE: Fundamental Ratings
NVAX
SYRE
OUTLOOK RATING
1..100
7582
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
65
Fair valued
PROFIT vs RISK RATING
1..100
1007
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
7934
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SYRE's Valuation (65) in the Pharmaceuticals Major industry is in the same range as NVAX (86) in the Biotechnology industry. This means that SYRE’s stock grew similarly to NVAX’s over the last 12 months.

SYRE's Profit vs Risk Rating (7) in the Pharmaceuticals Major industry is significantly better than the same rating for NVAX (100) in the Biotechnology industry. This means that SYRE’s stock grew significantly faster than NVAX’s over the last 12 months.

SYRE's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as NVAX (100) in the Biotechnology industry. This means that SYRE’s stock grew similarly to NVAX’s over the last 12 months.

SYRE's Price Growth Rating (34) in the Pharmaceuticals Major industry is somewhat better than the same rating for NVAX (79) in the Biotechnology industry. This means that SYRE’s stock grew somewhat faster than NVAX’s over the last 12 months.

SYRE's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as NVAX (100) in the Biotechnology industry. This means that SYRE’s stock grew similarly to NVAX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVAXSYRE
RSI
ODDS (%)
Bearish Trend 15 days ago
89%
Bearish Trend 15 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 15 days ago
87%
Bullish Trend 15 days ago
72%
Momentum
ODDS (%)
Bearish Trend 15 days ago
86%
Bearish Trend 15 days ago
86%
MACD
ODDS (%)
Bearish Trend 15 days ago
85%
Bearish Trend 15 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 15 days ago
90%
Bearish Trend 15 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 15 days ago
88%
Bullish Trend 15 days ago
82%
Advances
ODDS (%)
Bullish Trend about 1 month ago
82%
Bullish Trend 25 days ago
81%
Declines
ODDS (%)
Bearish Trend 15 days ago
90%
Bearish Trend 20 days ago
86%
BollingerBands
ODDS (%)
N/A
Bearish Trend 15 days ago
90%
Aroon
ODDS (%)
Bullish Trend 15 days ago
83%
Bullish Trend 15 days ago
86%
View a ticker or compare two or three
Ad is loading...
NVAXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
SYREDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DFETX17.810.06
+0.34%
DFA Emerging Markets II
AIGGX14.04N/A
N/A
Aristotle Growth Equity I-2
FAGAX147.54-0.01
-0.01%
Fidelity Advisor Growth Opps A
PAEEX20.11-0.06
-0.30%
Putnam Dynamic Asset Allocation Gr R6
GTLIX24.06-0.11
-0.46%
Glenmede Quant US Large Cap Core EqInstl

NVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with CRSP. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVAX
1D Price
Change %
NVAX100%
-2.72%
CRSP - NVAX
47%
Loosely correlated
+0.03%
THRD - NVAX
42%
Loosely correlated
-7.42%
XNCR - NVAX
38%
Loosely correlated
-0.77%
SYRE - NVAX
38%
Loosely correlated
-2.29%
MRNA - NVAX
35%
Loosely correlated
-0.90%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with BDTX. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then BDTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
-2.29%
BDTX - SYRE
60%
Loosely correlated
-2.76%
ACIU - SYRE
51%
Loosely correlated
-6.08%
THRD - SYRE
49%
Loosely correlated
-7.42%
RXRX - SYRE
48%
Loosely correlated
-5.92%
SNPX - SYRE
47%
Loosely correlated
-2.03%
More